Amit Kaushal

US Patent:

20130143755, Jun 6, 2013

Filed:

Mar 25, 2011

Appl. No.:

13/635667

Inventors:

Minnie M. Sarwal - Portola Valley CA, US
Tara Sigdel - Palo Alto CA, US
Amit Kaushal - Los Altos CA, US
Li Li - Fremont CA, US
Wenzhong Xiao - San Jose CA, US
Atul J. Butte - Menlo Park CA, US
Purvesh Khatri - Stanford CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

G01N 33/68
C12Q 1/68

US Classification:

506 9, 506 12

Abstract:

Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

US Patent:

20170227549, Aug 10, 2017

Filed:

Nov 22, 2016

Appl. No.:

15/359308

Inventors:

- Stanford CA, US
Tara Sigdel - Palo Alto CA, US
Amit Kaushal - Mountain View CA, US
Li Li - Stanford CA, US
Wenzhong Xiao - San Jose CA, US
Atul J. Butte - Menlo Park CA, US
Purvesh Khatri - Menlo Park CA, US

International Classification:

G01N 33/68
C12Q 1/68

Abstract:

Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.